Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma | BSE | Healthcare | Pharmaceuticals | ₹4.20T | 36.5x | 1.28 | ₹1,749.50 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.8% Upside | Upgrade to Pro+ | |
Sun Pharma | NSE | Healthcare | Pharmaceuticals | ₹4.20T | 36.5x | 1.28 | ₹1,749.80 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.9% Upside | Upgrade to Pro+ | |
Divi's Labs | NSE | Healthcare | Pharmaceuticals | ₹1.63T | 78.8x | 2.15 | ₹6,140.55 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Divi's Labs | BSE | Healthcare | Pharmaceuticals | ₹1.63T | 78.8x | 2.15 | ₹6,140.45 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Cipla | NSE | Healthcare | Pharmaceuticals | ₹1.19T | 23.8x | 0.68 | ₹1,472.25 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.2% Upside | Upgrade to Pro+ | |
Cipla | BSE | Healthcare | Pharmaceuticals | ₹1.19T | 23.8x | 0.67 | ₹1,472.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.4% Upside | Upgrade to Pro+ | |
Torrent Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.10T | 59x | 2.37 | ₹3,259.40 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
Torrent Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.10T | 59x | 2.36 | ₹3,258.60 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.6% Upside | Upgrade to Pro+ | |
Mankind Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.79 | ₹2,518.60 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
Mankind Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.79 | ₹2,518.40 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | BSE | Healthcare | Pharmaceuticals | ₹1.03T | 19.2x | 6.99 | ₹1,240.65 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | NSE | Healthcare | Pharmaceuticals | ₹1.03T | 19.2x | 6.99 | ₹1,240.40 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | NSE | Healthcare | Pharmaceuticals | ₹1T | 22x | 0.43 | ₹994.15 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | BSE | Healthcare | Pharmaceuticals | ₹1T | 22x | 0.43 | ₹993.95 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Lupin | BSE | Healthcare | Pharmaceuticals | ₹1T | 37.9x | 0.37 | ₹2,199.55 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Lupin | NSE | Healthcare | Pharmaceuticals | ₹1T | 37.9x | 0.37 | ₹2,201.15 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.2% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | BSE | Healthcare | Pharmaceuticals | ₹692.14B | 19.9x | 0.34 | ₹1,191.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | NSE | Healthcare | Pharmaceuticals | ₹692.14B | 19.9x | 0.34 | ₹1,191.70 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | |
Abbott India | NSE | Healthcare | Pharmaceuticals | ₹633.15B | 47.3x | 2.28 | ₹29,799.60 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
Abbott India | BSE | Healthcare | Pharmaceuticals | ₹633.15B | 47.3x | 2.28 | ₹29,796.40 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd BO | BSE | Healthcare | Pharmaceuticals | ₹615.92B | 29x | 0.59 | ₹5,154.90 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.3% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd | NSE | Healthcare | Pharmaceuticals | ₹615.92B | 29x | 0.59 | ₹5,151.35 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.4% Upside | Upgrade to Pro+ | |
Glenmark Pharma | BSE | Healthcare | Pharmaceuticals | ₹434.61B | -49.5x | 0.04 | ₹1,540.20 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Glenmark Pharma | NSE | Healthcare | Pharmaceuticals | ₹434.61B | -49.5x | 0.04 | ₹1,540.15 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Ipca Laboratories | NSE | Healthcare | Pharmaceuticals | ₹382.40B | 57.7x | 1.59 | ₹1,507.25 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Ipca Laboratories | BSE | Healthcare | Pharmaceuticals | ₹382.40B | 57.7x | 1.59 | ₹1,506.20 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | NSE | Healthcare | Pharmaceuticals | ₹373.44B | 55.2x | 7.89 | ₹2,208.15 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | BSE | Healthcare | Pharmaceuticals | ₹373.44B | 55.2x | 7.89 | ₹2,204.40 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Laurus Labs | NSE | Healthcare | Pharmaceuticals | ₹345.85B | 172.2x | 24.24 | ₹641.35 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.2% Downside | Upgrade to Pro+ | |
Laurus Labs | BSE | Healthcare | Pharmaceuticals | ₹345.85B | 172.2x | 24.24 | ₹641.35 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Healthcare | Pharmaceuticals | ₹336.16B | 37.4x | 1.63 | ₹2,689.40 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.1% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd | NSE | Healthcare | Pharmaceuticals | ₹336.16B | 37.4x | 1.64 | ₹2,691.70 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19% Upside | Upgrade to Pro+ | |
Piramal Pharma | BSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.79 | ₹226.55 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Piramal Pharma | NSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.78 | ₹226.46 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Suven Pharma | NSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.65 | ₹1,157.65 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Suven Pharma | BSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.65 | ₹1,155.20 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.2% Upside | Upgrade to Pro+ | |
J.B. Chemicals&Pharma | BSE | Healthcare | Pharmaceuticals | ₹260.45B | 40.5x | 1.85 | ₹1,673.75 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.2% Upside | Upgrade to Pro+ | |
J.B. Chemicals&Pharma | NSE | Healthcare | Pharmaceuticals | ₹260.45B | 40.5x | 1.84 | ₹1,671.25 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.9% Upside | Upgrade to Pro+ | |
Wockhardt | BSE | Healthcare | Pharmaceuticals | ₹259.85B | -81.3x | -1.96 | ₹1,602.50 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wockhardt | NSE | Healthcare | Pharmaceuticals | ₹259.85B | -81.3x | -1.96 | ₹1,599.35 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gland | NSE | Healthcare | Pharmaceuticals | ₹249.86B | 35.4x | -34.8 | ₹1,516.60 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2% Upside | Upgrade to Pro+ | |
Gland | BSE | Healthcare | Pharmaceuticals | ₹249.86B | 35.4x | -34.73 | ₹1,516.40 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.5% Upside | Upgrade to Pro+ | |
Concord Biotech | BSE | Healthcare | Pharmaceuticals | ₹245.03B | 60.6x | 8.52 | ₹2,342.25 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.8% Downside | Upgrade to Pro+ | |
Concord Biotech | NSE | Healthcare | Pharmaceuticals | ₹245.03B | 60.6x | 8.6 | ₹2,345.60 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.7% Downside | Upgrade to Pro+ | |
Natco Pharma | BSE | Healthcare | Pharmaceuticals | ₹236.32B | 12.1x | 0.15 | ₹1,318.70 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.9% Upside | Upgrade to Pro+ | |
Natco Pharma | NSE | Healthcare | Pharmaceuticals | ₹236.32B | 12.1x | 0.15 | ₹1,319.40 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
Emcure Pharmaceuticals | BSE | Healthcare | Pharmaceuticals | ₹229.73B | 39.1x | -6.43 | ₹1,210.30 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.7% Upside | Upgrade to Pro+ | |
Emcure Pharmaceuticals | NSE | Healthcare | Pharmaceuticals | ₹229.73B | 39.1x | -6.44 | ₹1,212.75 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.2% Upside | Upgrade to Pro+ | |
Pfizer Ltd | BSE | Healthcare | Pharmaceuticals | ₹199.36B | 32.2x | 1.5 | ₹4,363.10 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
Pfizer Ltd | NSE | Healthcare | Pharmaceuticals | ₹199.36B | 32.2x | 1.5 | ₹4,357.90 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ |